Brief: NIH Says Tecovirimat Is Safe But Ineffective As Treatment For Clade II Mpox
12/03/2025 17:08
March 12 (Reuters) - NIH: NIH: TECOVIRIMAT IS SAFE BUT INEFFECTIVE AS TREATMENT FOR CLADE II MPOX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SIGA Technologies
See all newsBrief: Siga Secures Contract Valued At Up To $15 Million From Canadian Department Of National Defence To Purchase Tpoxx®
SIGA Technologies Q2 revenue, profit drop as contract ends
SIGA Technologies Q1 revenue falls, net loss widens
Brief: SIGA Technologies Q1 EPS USD -0.05
Brief: EMA Recommends Restricting Use Of Tecovirimat SIGA